STOCK TITAN

BioStem Technologies (BSEM) Stock News, Jul-Oct 2025

BSEM NASDAQ

BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.

BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.

Rhea-AI Summary

BioStem Technologies (OTC: BSEM) reported top-line randomized controlled trial results published in the International Journal of Tissue Repair showing BioRetain (BR-AC) produced higher lasting wound-closure rates than standard of care in hard-to-heal diabetic foot ulcers (DFUs).

Key metrics: probability of lasting closure 53% for BR-AC vs 31% for standard of care over a 12-week period; study enrolled 71 patients across 11 U.S. sites, initiated Q4 2024, with lasting closure defined as remaining closed for 4 weeks. Future publications will report secondary endpoints including time to closure, wound area/volume change, and number of BR-AC applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET.

The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Brandon Poe, CFO. Conference ID and dial-in numbers are provided for North America and international participants, and a live webcast link is available for online attendees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences earnings date
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) announced that its Audit Committee approved the appointment of KPMG LLP as its independent registered public accounting firm, ending its engagement with Marcum (now CBIZ) effective Oct 22, 2025. The company said KPMG was selected for its life sciences expertise to support BioStem's growth and planned uplist to Nasdaq following completion of full-year 2024 and 2025 audits. Management emphasized the uplisting as a priority to improve liquidity, visibility, and market valuation. The company also stated there were no disagreements with Marcum during the two most recent fiscal years and any interim period before the dismissal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) has expanded its partnership with the Florida Panthers as the new sponsor of the "Heroes Among Us" program for its 13th season in 2025-26. The program, which has honored over 500 military veterans since 2013, recognizes one military hero at each Panthers home game with a national anthem dedication and video tribute.

BioStem will also continue supporting the "Seats for Service" program, which has provided 125 seats to veterans since the 2024-25 season. The initiative offers veterans four game tickets, parking, and a $50 food credit at Amerant Bank Arena. This partnership aligns with BioStem's upcoming launch of their American Amnion product line for military wound care and reflects the company's commitment to veterans, exemplified by their co-founder Andrew Van Vurst, a U.S. Marine Corps veteran.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
partnership
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) announced its participation in the Symposium for Advanced Wound Care (SAWC) Fall meeting in Las Vegas from September 3-6, 2025. The company is co-exhibiting with strategic partner Venture Medical, LLC to showcase their combined wound care management solutions.

The exhibition features three scientific posters highlighting BioStem's proprietary BioREtain® technology and allograft portfolio. The company's leading products, AmnioWrap2® and Vendaje AC®, are exclusively available through Venture Medical and integrated with the Venture OneView™ platform for streamlined chronic wound care management.

The event includes scheduled booth presentations on wound care topics and a sponsored breakfast symposium titled "Navigating the Future of Wound Care," focusing on clinical evidence, allograft selection, and practice management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC:BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has announced its participation in two upcoming investor conferences in New York.

The company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8, 2025, at 3:20 PM ET, followed by a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 AM ET. Investors can access live and archived webcasts of both presentations through BioStem's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
conferences
Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announced a significant insider purchase by its Chairman and CEO, Jason Matuszewski.

On August 19, 2025, Matuszewski acquired 15,500 shares through two transactions: 2,500 shares at $6.28 and 13,000 shares at $6.51, totaling approximately $100,000. Following these purchases, his total ownership stands at 1,145,362 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM) reported preliminary Q2 2025 financial results, marking its sixth consecutive quarter of positive adjusted EBITDA. The company generated net revenue of $49.3M, down 34% YoY, with adjusted EBITDA of $2.5M compared to $10.1M in Q2 2024. The company reported a GAAP net loss of $0.6M or ($0.03) per share.

Key developments include the appointment of Brandon Poe as CFO, completion of enrollment in a clinical trial for BioREtain® Amnion Chorion, and expansion of intellectual property with three new U.S. patent applications. The company's cash position strengthened to $30.8M, up $4.1M from Q1. BioStem continues to pursue Nasdaq uplisting and is working through historical financial statement audits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.14%
Tags
-
Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived advanced wound care products, has appointed Brandon Poe as its new Chief Financial Officer. Poe, who has served on BioStem's Board since 2022, brings over 25 years of healthcare and life sciences experience, including senior finance roles at Midi Health, Jumpcode Genomics, and Illumina.

The appointment comes at a strategic time as BioStem pursues market expansion and Nasdaq uplisting plans. The former CFO, Michael Fortunato, will transition to the role of Chief Accounting Officer. Poe's extensive background in capital markets and operational excellence, combined with his familiarity with BioStem's business, positions him to support the company's growth initiatives and BioREtain® platform development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.14%
Tags
none
Rhea-AI Summary

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, will release its Q2 2025 financial results on August 14, 2025, followed by a conference call at 4:30 PM ET.

The conference call will feature CEO Jason Matuszewski and CFO Michael Fortunato discussing quarterly results and providing updates on the company's Form 10 filing and planned Nasdaq uplisting. The company's core business focuses on manufacturing allografts using their proprietary BioREtain® processing method, with products including AmnioWrap2™, VENDAJE®, and American Amnion™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
conferences earnings date

FAQ

What is the current stock price of BioStem Technologies (BSEM)?

BioStem Technologies (BSEM) last closed at $0.8182.

What is the market cap of BioStem Technologies (BSEM)?

The market cap of BioStem Technologies (BSEM) is approximately $15.7M.